Emopamil
Emopamil is a calcium channel blocker and sigma receptor ligand that has been studied for its potential use in the treatment of cardiovascular disease.
Pharmacology[edit | edit source]
Emopamil acts as a calcium channel blocker, inhibiting the influx of calcium ions into cardiac and smooth muscle cells. This action can lead to a decrease in blood pressure and a reduction in heart rate. Emopamil also has affinity for sigma receptors, which are thought to be involved in various physiological processes, including the regulation of neurotransmitter release.
Clinical Use[edit | edit source]
While emopamil has been studied for its potential use in the treatment of cardiovascular disease, it has not been approved for this use by any regulatory authority. The drug's effects on the cardiovascular system, including its ability to lower blood pressure and reduce heart rate, could potentially make it useful in the treatment of conditions such as hypertension and angina pectoris.
Side Effects[edit | edit source]
As with other calcium channel blockers, potential side effects of emopamil could include dizziness, headache, flushing, and edema. Due to its sigma receptor activity, emopamil could also potentially cause neurological side effects.
See Also[edit | edit source]
Emopamil Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD